Cell and Gene Therapy Market Size, Share and Growth Outlook, 2026

Cell and Gene Therapy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cell and Gene Therapy Market size is forecast to increase from $12.42 Billion in 2026 to $48.62 Billion in 2034 at a CAGR of 18.6% between 2026 and 2034.

The Cell and Gene Therapy market report provides detailed analysis and outlook of Cell and Gene Therapy segments including By Therapy Type (Cell Therapy, Gene Therapy ), By Vector Type (Viral Vectors, Non-Viral Vectors ), By Application (Oncology, Rare & Genetic Disorders, Musculoskeletal, Cardiology & Neurology, Ophthalmology, Immunology), By Delivery Mode (Ex vivo Administration, In vivo Administration), By End-User (Hospitals & Clinics, Specialty Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cell and Gene Therapy Industry Overview

Regulatory Flexibility and Technological Innovation Reshaping the Industry

The cell and gene therapy industry is entering a new phase characterized by regulatory modernization, manufacturing flexibility, and increasing investment in next-generation therapeutic platforms. As developers advance increasingly complex cellular and genetic medicines for oncology, rare diseases, and regenerative medicine applications, regulatory agencies and industry stakeholders are working to streamline development pathways while maintaining product quality and patient safety. These efforts are supporting a more efficient transition from early-stage clinical development to pivotal studies and eventual commercialization.

Adaptive Regulatory Frameworks Supporting Clinical Advancement

A major development within the cell and gene therapy industry is the introduction of greater regulatory flexibility for chemistry, manufacturing, and control activities. The U.S. Food and Drug Administration established an adaptive framework governing CMC requirements for human cellular and gene therapy products. Under the updated policy, the Center for Biologics Evaluation and Research will permit certain minor manufacturing modifications supported by basic validation data to proceed without triggering extensive comparability requirements as programs move from phase 1 studies into pivotal clinical testing. This regulatory approach is intended to reduce development delays while preserving manufacturing oversight and product quality standards.

Modernized Manufacturing Requirements Reducing Development Barriers

The FDA has also addressed longstanding manufacturing challenges through its Chemistry, Manufacturing, and Controls Flexibilities framework. The agency clarified that developers are no longer required to produce three identical Process Performance Qualification lots as an absolute condition for Biologics License Application submissions. Instead, CBER reviewers can evaluate customized PPQ strategies based on the specific scale and characteristics of individual programs. This reform is particularly important for ultra-rare disease therapies, where manufacturing large numbers of qualification lots may be impractical. The revised approach provides greater flexibility while maintaining scientific rigor in manufacturing validation processes.

Industry Shift Toward In Vivo Therapeutic Platforms

Strategic investment priorities across the cell and gene therapy industry are increasingly shifting toward in vivo treatment technologies. Discussions presented during the JP Morgan Healthcare Conference highlighted how major pharmaceutical companies are redirecting capital from traditional ex vivo cell therapy platforms toward advanced in vivo gene delivery systems. These technologies are designed to modify immune cells directly within the patient’s body through localized gene transport mechanisms. By eliminating the need for complex ex vivo cell processing, lymphodepletion regimens, and prolonged hospital-based treatment workflows, in vivo approaches have the potential to simplify therapy administration and improve accessibility. This transition is influencing research priorities, manufacturing investments, and platform development strategies across the broader cell and gene therapy ecosystem.

Cell and Gene Therapy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cell and Gene Therapy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Gilead Sciences, Inc. (Kite Pharma), Novartis AG, Johnson & Johnson (Janssen), Bristol Myers Squibb Company, Sarepta Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Krystal Biotech, Inc., Iovance Biotherapeutics, Inc., Autolus Therapeutics plc, Legend Biotech Corporation. The Cell and Gene Therapy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cell and Gene Therapy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cell and Gene Therapy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cell and Gene Therapy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cell and Gene Therapy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cell and Gene Therapy Market Competitive Benchmarking and Company Analysis

Leading companies in Cell and Gene Therapy industry include- Gilead Sciences, Inc. (Kite Pharma), Novartis AG, Johnson & Johnson (Janssen), Bristol Myers Squibb Company, Sarepta Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, Krystal Biotech, Inc., Iovance Biotherapeutics, Inc., Autolus Therapeutics plc, Legend Biotech Corporation. The Cell and Gene Therapy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cell and Gene Therapy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cell and Gene Therapy market remains one of the strongest-performing segments in the country.
The US Cell and Gene Therapy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cell and Gene Therapy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cell and Gene Therapy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cell and Gene Therapy markets

Canada's strong Cell and Gene Therapy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cell and Gene Therapy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cell and Gene Therapy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cell and Gene Therapy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cell and Gene Therapy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cell and Gene Therapy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cell and Gene Therapy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cell and Gene Therapy sales through 2034

France Cell and Gene Therapy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cell and Gene Therapy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cell and Gene Therapy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cell and Gene Therapy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cell and Gene Therapy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cell and Gene Therapy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cell and Gene Therapy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cell and Gene Therapy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cell and Gene Therapy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cell and Gene Therapy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cell and Gene Therapy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cell and Gene Therapy Market Segmentation

By Therapy Type
Cell Therapy
Gene Therapy
By Vector Type
Viral Vectors
Non-Viral Vectors
By Application
Oncology
Rare & Genetic Disorders
Musculoskeletal
Cardiology & Neurology
Ophthalmology
Immunology
By Delivery Mode
Ex vivo Administration
In vivo Administration
By End-User
Hospitals & Clinics
Specialty Clinics
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes

Top Companies in Cell and Gene Therapy Industry

Gilead Sciences, Inc. (Kite Pharma)
Novartis AG
Johnson & Johnson (Janssen)
Bristol Myers Squibb Company
Sarepta Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated
Krystal Biotech, Inc.
Iovance Biotherapeutics, Inc.
Autolus Therapeutics plc
Legend Biotech Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025